Marinomed Biotech AG (DE:93Z)
FRANKFURT:93Z
Germany Market

Marinomed Biotech AG (93Z) Income Statement

0 Followers

Marinomed Biotech AG Income Statement

Last quarter (Q ), Marinomed Biotech AG's total revenue was €4.18M, a decrease of -29.29% from the same quarter last year. In Q, Marinomed Biotech AG's net income was €-608.90K. See Marinomed Biotech AG’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
€ 11.28M€ 11.28M€ 11.63M€ 8.12M€ 6.14M€ 4.67M
Cost of Revenue
€ 9.14M€ 9.14M€ 10.20M€ 8.77M€ 6.66M€ 4.83M
Gross Profit
€ 2.14M€ 2.14M€ 1.42M€ -641.70K€ -512.30K€ -165.50K
Operating Expense
€ 7.01M€ 7.01M€ 5.57M€ 5.17M€ 5.78M€ 5.00M
Operating Income
€ -4.87M€ -4.87M€ -4.14M€ -5.82M€ -6.29M€ -5.16M
Net Non Operating Interest Income Expense
€ -1.52M€ -1.52M€ -1.55M€ -190.60K€ -595.10K€ -1.27M
Other Income Expense
------
Pretax Income
€ -6.39M€ -6.39M€ -5.69M€ -6.01M€ -7.21M€ -12.09M
Tax Provision
€ 6.80K€ 6.80K€ 197.10K€ 3.50K€ 4.40K€ 3.50K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
€ -6.40M€ -6.40M€ -5.89M€ -6.01M€ -7.22M€ -12.10M
Basic EPS
€ -4.26€ -4.30€ -4.00€ -4.10--
Diluted EPS
€ -4.26€ -4.30€ -4.00€ -4.10--
Basic Average Shares
€ 6.01M€ 1.50M€ 1.48M€ 1.47M--
Diluted Average Shares
€ 6.01M€ 1.50M€ 1.48M€ 1.47M--
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
----€ 4.60K€ 90.10K
Total Expenses
€ 16.15M€ 16.15M€ 15.77M€ 13.94M€ 12.44M€ 9.83M
Net Income From Continuing And Discontinued Operation
€ -6.40M€ -6.40M€ -5.89M€ -6.01M€ -7.22M€ -12.10M
Normalized Income
€ -6.40M€ -6.40M€ -5.89M€ -6.01M€ -6.96M€ -7.85M
Interest Expense
€ 2.51M€ 2.51M€ 1.51M€ 713.60K€ 665.40K€ 1.50M
EBIT
€ -3.88M€ -3.88M€ -4.19M€ -5.29M€ -6.55M€ -10.60M
EBITDA
€ -3.21M€ -3.21M€ -3.58M€ -4.86M€ -6.22M€ -10.36M
Currency in EUR

Marinomed Biotech AG Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis